LXRs also activate SREBP2, a nuclear transcription factor that regulates the expression of enzymes associated with cholesterol metabolism, as demonstrated by a 7-year follow-up prospective study that showed coding polymorphism can predict the occurrence and development of NAFLD (40). The gene discussed is SREBF2; the disease is metabolic dysfunction-associated steatotic liver disease.